Cancers have the ability to disrupt immune response by interfering with adaptive immunity. Blocking checkpoint pathways has become a target for pharmacological research in lung cancer with particular focus on peptides PD-1 and CTLA-4. A number of immune check-point inhibitors (ICIs) targeting both PD-1 and CTLA-4 pathways are under investigation within clinical trials, of which Nivolumab, Pembrolizumab and Atezolizumab have already been approved for lung cancer treatment by both FDA and EMA. Employed as single-agents in current practice for the treatment of advanced non-small cell lung cancer (NSCLC) ICIs have exhibited advantages in terms of overall survival and response rate with some responses being durable. Evaluating combinations of different inhibitors, dosing and sequencing within a multimodal therapy approach, together with better management of toxicity represents a new challenge for future research of therapy targeting immune check-points.
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.coph.2018.02.006|
|Codice identificativo ISI:||WOS:000438324100009|
|Codice identificativo Scopus:||2-s2.0-85043333441|
|Titolo:||Targeting immune checkpoints in non small cell lung cancer|
|Appare nelle tipologie:||1.1 Articolo in rivista|